You are here: Industry Insights > Opdivo

News List

BMS and Clovis Oncology announce a broad clinical collaboration to evaluate combination of Opdivo an cphi-online
August 01, 2017
Pivotal Phase III trials planned for 2017 will evaluate Rubraca + Opdivo, Rubraca as monotherapy, and Opdivo as monotherapy in first line maintenance treatment for advanced ovarian and advanced triple-negative breast cancers.
Merck's Keytruda speeds its I-O market-share grab as Bristol-Myers' Opdivo declines fiercepharma
July 21, 2017
The latest immuno-oncology market-share numbers are out, and they show that Merck & Co.’s Keytruda is not only gaining on Bristol-Myers Squibb archrival Opdivo, but it’s picked up the pace, too.
Novartis, BMS in Opdivo Clinical Collaboration contractpharma
June 07, 2017
To investigate Mekinist with Opdivo and Opdivo + Yervoy in metastatic colorectal cancer
EU approves Opdivo for bladder cancer pharmatimes
June 06, 2017
Bristol-Myers Squibb’s Opdivo has picked up approval for its eighth indication in Europe, having won clearance for the treatment of a subset of patients with metastatic urothelial carcinoma (mUC).
Array, BMS in Opdivo Clinical Combo Alliance contractpharma
May 31, 2017
To investigate Array's binimetinib in combination with BMS' Opdivo and Opdivo + Yervoy regimen in colorectal cancer
Bavarian Nordic, BMS kick off phase 2 testing Prostvac with Opdivo, Yervoy in presurgery prostate ca fiercepharma
April 26, 2017
In a new phase 2 trial, Bavarian Nordic and Bristol-Myers Squibb plan to test the power of the Big Pharma's immunotherapies when paired up with the vaccine maker's prostate-cancer fighter Prostvac.
BMS and Apexigen collaborate to evaluate Opdivo in combination with APX005M in advanced solid tumour cphi-online
April 14, 2017
Study to evaluate potential of APX005M plus Opdivo to activate antigen-presenting cells in the tumour micro-environment to demonstrate enhanced anti-tumour activity.
BMS and Incyte to advance the combination of Opdivo and Epacadostat into first-line registrational t cphi-online
April 05, 2017
Companies to initiate Phase III registrational trials in first-line NSCLC across the spectrum of PD-L1 expression and first-line head and neck cancer in 2017.
BMS receives positive CHMP opinion recommending Opdivo for head and neck cancer cphi-online
March 29, 2017
Opdivo already approved by the EC for six indications in four distinct tumour types.
BMS Receives Positive CHMP Opinion Recommending Opdivo for the Treatment of Squamous Cell Cancer of americanpharmaceuticalreview
March 27, 2017
Bristol-Myers Squibb Company has announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Opdivo...

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page